Executive Summary
Redo-TAVI with the SAPIEN 3 platform achieved a 95.1% implant success rate and 3.5% 30-day mortality across 143 patients with failed transcatheter valves in the prospective international ReTAVI registry — reassuring early data for the lifetime-management question, but with mean gradient reduction of only 12 mmHg overall and no durability signal yet, which complicates rather than settles the case for TAVI-first in patients under 70. Long-term echocardiographic data from the OCEAN-TAVI 7-year analysis reignited the BEV-versus-SEV debate in women with small annuli, while a National Inpatient Sample propensity analysis flipped the script in patients with pre-existing pacemakers, where TAVR's usual conduction-disturbance penalty disappears.
- ReTAVI 30-day stroke 0.7%, coronary obstruction 1.4%, pacemaker 6.3% — a clean early safety profile across heterogeneous failed-THV substrates (EuroIntervention).
- OCEAN-TAVI: BEV had smaller EOA and higher gradients than SEV in women throughout 7 years, yet showed lower mortality (51.5% vs 57.4%) and stroke (10.8% vs 16.7%) (JACC: Asia).
- One-third of TAVI patients with LF-LG preserved-EF AS cluster into an HFpEF/AF phenotype with worse 5-year mortality, suggesting a missed GDMT opportunity (ESC Heart Failure).
- In patients with pre-existing PPM/ICD, TAVR halved in-hospital mortality vs SAVR (0.80% vs 2.59%) in 501 matched pairs (Cardiology in Review).
- CASPER algorithm for bicuspid TAVI sizing produced 6% moderate PVL and 25% pacemaker rate with self-expanding valves — hypothesis-generating without a control arm (CJC).
What to watch: Medtronic reports earnings June 3 with EPS consensus $1.55 and revenue $9.61B; Structural Heart commentary will frame the Evolut narrative against ReTAVI and a 27% six-month stock drawdown.
Aortic Valve (TAVR/TAVI)
Redo-TAVI is now operationally validated; the durability question is untouched. The ReTAVI registry (N=143, 59 centers, median age 84, median STS 7.0%) delivered 95.1% implant success with SAPIEN 3 inside failed SAPIEN, Evolut, and ACURATE platforms — 30-day mortality 3.5%, stroke 0.7%, coronary obstruction 1.4%. Gradient reduction was driven by stenotic-failure cases (Δ-29 mmHg) while regurgitant failures (48.6% of cohort) saw modest hemodynamic change. This is the cleanest early-safety dataset to date for THV-in-THV, but it is a 30-day report in an elderly high-risk cohort — exactly the population where lifetime management matters least. ESC 2025 Class I recommends TAVI in patients ≥70 with tricuspid anatomy, but explicitly flags that lifetime planning requires CT-based anatomical analysis for future valve-in-valve feasibility; ReTAVI does not address whether a 60-year-old's first TAVI sets up a workable second valve. ACC/AHA 2020 still favors SAVR under 65 on durability grounds, and ReTAVI doesn't move that line. Separately, the case report of Stanford Type A dissection after self-expanding TAVI requiring Bentall is a reminder that pop-out and recapture maneuvers carry real root-injury risk — the kind of complication that simply does not occur with SAVR.
In women with small annuli, OCEAN-TAVI 7-year data (N=1,488 matched) showed BEV had worse hemodynamics throughout follow-up (smaller EOA, higher mean gradients) yet lower all-cause mortality (51.5% vs 57.4%, P=0.021) and stroke (10.8% vs 16.7%, P=0.008). Multivariable adjustment eliminated the valve-type signal — meaning unmeasured selection drives the PSM result. Both valves remain reasonable; neither is settled. The CASPER registry (N=101, single-arm, no comparator) reported a workable bicuspid sizing strategy with 6% moderate PVL but a 25% pacemaker rate — high enough that, combined with ESC 2025 Class IIb status for bicuspid TAVI, surgery remains the default for young BAV patients with aortopathy.
Two phenotyping papers reframe low-flow AS. The Dutch-German cluster analysis identified an HFpEF/AF subgroup comprising one-third of LF-LG preserved-EF TAVI patients, with 1- and 5-year mortality matching classical LF-LG — these patients need SGLT2 inhibitors and MRAs alongside valve replacement, not just a valve. The Mount Sinai flow-normalization analysis (N=174) found only 16% of low-flow patients show concordant LVEF and SVi improvement post-TAVR; 40.8% improve in neither. The valve fixes the gradient; it does not fix the ventricle.
The EMPIRE I 1-year ALLEGRA/IMPERIA data (N=137, 11 European centers) showed 0% structural valve deterioration, 5.9% bioprosthetic dysfunction, and a 14.3% pacemaker rate — competitive numbers from a small, single-arm pre-market study. The EuroIntervention review on TAVI and coronary interventions reinforces what ESC 2025 lifetime-management language already implies: commissural alignment, neo-skirt height, and coronary access geometry need to be planned at the index procedure, not at the redo.
Mitral Valve (MitraClip, PASCAL, TMVR)
TEER for cancer-therapy-related cardiac dysfunction is now a documented reverse-remodeling pathway, but a single case is not a guideline. The International Heart Journal case report describes a 47-year-old post-anthracycline/anti-HER2 patient whose LVEF recovered from 26% to 61% twelve months after TEER for severe secondary MR — driven by reverse remodeling rather than mechanical correction alone. The mechanism is consistent with COAPT-era thinking, but CTRCD patients were not enrolled in COAPT or RESHAPE-HF2, and ESC 2025's Class I recommendation for TEER in ventricular SMR explicitly relies on COAPT-like criteria. ACC/AHA 2020 Class IIa for the same indication is equally silent on CTRCD. This case is hypothesis-generating; routine TEER referral for CTRCD without GDMT optimization is not supported. The accompanying Internal Medicine editorial on LVEF dynamics after MitraClip pushes for phenotype-specific interpretation — afterload mismatch is one of several mechanisms, and lumping all post-TEER LVEF changes together obscures the underlying biology. Surgical mitral repair remains the durable comparator for primary MR; for secondary MR in patients meeting COAPT criteria, TEER is now the default in Europe.
Tricuspid Valve (TriClip, TTVR)
A first-in-human heterotopic cross-caval TTVR landed in EuroIntervention without an abstract — the case report is a procedural feasibility signal, not a clinical outcomes statement. Heterotopic caval valves address regurgitant flow without engaging the tricuspid annulus, an approach that may suit patients with prohibitive anatomy for orthotopic TTVR but does not eliminate tricuspid regurgitation at its source. ESC 2025 Class IIa for transcatheter tricuspid treatment is grounded in TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — all orthotopic repair or replacement trials. Heterotopic approaches do not yet have a guideline pedigree, and surgical TR repair (ESC 2025 Class I for symptomatic primary TR, upgraded from ACC/AHA 2020 IIa) remains the comparator for patients with operable anatomy and preserved RV function. The too-late-referral problem persists: by the time heterotopic caval valves are on the table, RV failure is often already entrenched.
Surgical vs. Transcatheter Comparisons
The National Inpatient Sample 2016-2022 analysis of TAVR versus SAVR in patients with pre-existing PPM or ICD is the day's most interesting head-to-head. After propensity matching (501 pairs), TAVR had lower in-hospital mortality (0.80% vs 2.59%, OR 0.31, P=0.049), fewer MACCE, less stroke/TIA, less AKI, less bleeding, and shorter LOS — with no excess pacemaker procedures (the patients already have devices). This is administrative data, in-hospital only, no durability signal, no follow-up — but the logic is clean: TAVR's main long-term cost in younger patients is conduction disturbance, and in patients already paced, that cost is paid. [NOTABLE] Both ACC/AHA 2020 and ESC 2025 frameworks should explicitly address pre-existing CIED as a TAVR-favoring factor; neither currently does. Separately, the post-TAVI Type A dissection requiring Bentall is the kind of catastrophic complication that anchors the surgical counterpoint — SAVR doesn't dissect the root.
Device & Technology
The UNICORN technique feasibility report in EuroIntervention (no abstract) joins the ALLEGRA/IMPERIA EMPIRE I 1-year data as European device iterations chasing the Evolut/SAPIEN duopoly. EMPIRE I showed 0% structural valve deterioration at 12 months and full repositionability with the new delivery system — but a 14.3% pacemaker rate and 10.8% all-cause mortality in native AS patients at one year keeps ALLEGRA in the "competitive, not differentiated" category. The EuroIntervention review on TAVI-coronary interplay formalizes commissural alignment and access geometry as procedural-planning imperatives, not afterthoughts.
Valve Industry Stocks
Edwards is the standout. The rest of the sector — Medtronic, Abbott, Boston Scientific — has shed between 27% and 53% over six months, a sector-wide derating that no clinical news today explains. Anteris held onto its 86% six-month gain despite a 6% daily pullback.
Edwards Lifesciences (EW)
- Close $86.94, +0.54% on the day, +1.96% over six months — the only major valve name in the green.
- Market cap $50.1B, trailing P/E 46.99, forward P/E 25.84, beta 0.87, 52-week range $72.30-$88.72.
- Analyst target $96.65 (range $84-$110, 26 analysts), buy consensus.
- Next earnings July 23 (EPS est $0.74, revenue est $1.70B).
- Institutional flows visible today: Eurizon Capital invested $13.69M, with Norges Bank also adding.
Medtronic (MDT)
- Close $74.14, +0.44% on the day, -27.14% over six months — sitting at six-month lows.
- Market cap $95.2B, trailing P/E 20.71, forward P/E 12.24, beta 0.63, 52-week range $73.67-$106.33.
- Analyst target $106.56 (range $84-$121, 25 analysts), buy consensus implies 44% upside.
- Next earnings June 3 (EPS est $1.55, revenue est $9.61B) — the print bears on the Evolut narrative against ReTAVI.
Abbott (ABT)
- Close $86.59, +1.16% on the day, -31.59% over six months.
- Market cap $150.8B, trailing P/E 24.25, forward P/E 14.28, beta 0.65, 52-week range $81.97-$139.06.
- Analyst target $117.29 (range $92-$135, 24 analysts), buy consensus.
- Next earnings July 16 (EPS est $1.28, revenue est $12.53B). TriClip/Navitor pipeline narrative needs the next Structural Heart segment to stabilize.
Boston Scientific (BSX)
- Close $47.74, -1.19% on the day, -52.74% over six months — the sector's worst drawdown.
- Market cap $71.0B, trailing P/E 19.97, forward P/E 12.75, beta 0.62, 52-week range $47.37-$109.50.
- Analyst target $79.40 (range $55-$106, 30 analysts), strong-buy consensus implies 66% upside.
- Next earnings July 29 (EPS est $0.83, revenue est $5.38B). ACURATE neo2 appears as a failed-THV substrate in ReTAVI; durability questions persist.
Anteris Technologies (AVR.AX)
- Close A$11.50, -6.28% on the day, +86.39% over six months.
- Market cap A$1.1B, forward P/E -5.27 (pre-revenue), beta 0.59, 52-week range A$4.68-$13.80.
- Single analyst target A$13.00. DurAVR THV remains in pivotal-trial mode.
Sector outlook: the divergence between Edwards and the rest is not explained by today's clinical news. ReTAVI's positive read on SAPIEN 3 in failed THVs likely supports Edwards's lifetime-management story, but the 27-53% drawdowns at MDT, ABT, and BSX point to broader macro and pipeline concerns that single-day clinical readouts won't reverse. Medtronic's June 3 print is the next inflection.
Clinical Trial Updates
Aortic:
- NCT07614100 — Cerebral Microembolization During TAVI: BEV vs SEV. Status: NOT_YET_RECRUITING. Enrollment: 80. Sponsor: Ivan Zeljkovic. Addresses a head-to-head question OCEAN-TAVI raised today but could not answer mechanistically.
- NCT07604402 — TRanscatheter Aortic-Valve Implantation Without On-site Cardiac Surgery. Status: RECRUITING. Enrollment: 1,612. Sponsor: University Hospital of Ferrara. The post-TAVI Type A dissection case today is a reminder of why on-site cardiac surgery has been the default safety net.
The day's PubMed haul did not include updates from REPAIR-MR, PRIMARY, TRILUMINATE, CLASP TR, APOLLO, TRISCEND, PARTNER, or COAPT.
Forward look: Medtronic's June 3 earnings, set against a 27% six-month decline and a backdrop of competitive redo-TAVI data favoring SAPIEN 3, will set the tone for the structural heart trade through July.